A National Multicenter Study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with Radium-223.

Viviana FrantellizziFabio MonariManlio MasciaRenato CostaGiuseppe RubiniAngela SpanuAlessio FarcomeniElisa Lodi RizziniLuca CindoloAlessandra MurabitoValentina LavelliSusanna NuvoliLaura CosmaValeria DionisiAnna Giulia NappiMarco AndreolaGiuseppe De Vincentis

Published in: Aging clinical and experimental research (2020)

Radium-223 prolongs survival in both younger and older patients at the same baseline condition and is a good option in the symptomatic mCRPC setting compared to other agents.

Keyphrases

prostate cancer
middle aged
community dwelling
squamous cell carcinoma
free survival
small cell lung cancer
radical prostatectomy
physical activity
quality improvement